Overview
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
Status:
Withdrawn
Withdrawn
Trial end date:
2012-04-01
2012-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease. It is a 6-month study enrolling 651 patients in Japan, Hong Kong, Korea, and Republic of China. All patients completing the 6-month study will be eligible to receive PF-01913539 in an open-label extension trial (B1451031).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- Mild-to-Moderate Alzheimer's disease
- MMSE score 10-24 inclusive
Exclusion Criteria:
- Administration of anti-dementia drugs including cholinesterase-inhibitors or NMDA
receptor antagonists within 90 days
- Complication of other causes of dementia